Inventor

PARUCH KAMIL

US50 patents

⚠️ This page may combine multiple inventors who share the name “PARUCH KAMIL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

PARUCH KAMIL

SCHERING CORP

Imidazopyrazines as cyclin dependent kinase inhibitors

Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors

Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors

Substituted pyrazolo[1,5-a] pyrimidines as protein kinase inhibitors

Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors

Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors

N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors

Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors

Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors

Imidazopyrazines as cyclin dependent kinase inhibitors

Pyrazolotriazines as kinase inhibitors

Imidazopyridines as cyclin dependent kinase inhibitors

Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors

4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2H-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent kinase inhibitors

Imidazopyridines as cyclin dependent kinase inhibitors

Imidazopyrazines as cyclin dependent kinase inhibitors

17-β hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

Imidazopyrazines as protein kinase inhibitors

Pyrazolopyrimidines as cyclin dependent kinase inhibitors

17 β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors

Imidazopyrazines as cyclin dependent kinase inhibitors

Pyrazolotriazines as kinase inhibitors

Pyrazolotriazines as kinase inhibitors

17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors

Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors

Pyrazolopyrimidines as cyclin dependent kinase inhibitors

17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

Pyrazolopyrimidines as protein kinase inhibitors

Pyrazolopyridines as cyclin dependent kinase inhibitors

PHARMACOPEIA DRUG DISCOVERY

Pyrazolopyrimidines as cyclin dependent kinase inhibitors

Pyrazolopyrimidines as cyclin dependent kinase inhibitors

Pyrazolopyrimidines as cyclin dependent kinase inhibitors

Pyrazolopyrimidines as cyclin dependent kinase inhibitors

Pyrazolopyrimidines as cyclin dependent kinase inhibitors

Pyrazolopyrimidines as cyclin dependent kinase inhibitors

GUZI TIMOTHY J

Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors

Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors

Methods for inhibiting protein kinases

Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors

Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors

UNIV MASARYKOVA

Substituted aminothiazoles as inhibitors of nucleases

Substituted propanamides as inhibitors of nucleases

4-(1H-imidazol-5-yl)-1H-pyrrolo[2, 3-b] pyridines for use in the treatment of leukaemias, lymphomas and solid tumors

Pyrazolotriazines as inhibitors of nucleases

Furopyridines as inhibitors of protein kinases

SCHERING CORPOARTION

Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors